

# Theodore S Hong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1668191/publications.pdf>

Version: 2024-02-01

295  
papers

13,693  
citations

41344

49  
h-index

24982

109  
g-index

300  
all docs

300  
docs citations

300  
times ranked

17502  
citing authors

#	ARTICLE	IF	CITATIONS
1	Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. <i>Gut</i> , 2022, 71, 185-193.	12.1	34
2	Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 242-252.	1.5	4
3	A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer. <i>Annals of Surgery</i> , 2022, 275, 391-397.	4.2	15
4	Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, e502-e509.	4.2	6
5	Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. <i>European Radiology</i> , 2022, 32, 2470-2480.	4.5	9
6	Response prediction of neoadjuvant chemoradiation therapy in locally advanced rectal cancer using CT-based fractal dimension analysis. <i>European Radiology</i> , 2022, 32, 2426-2436.	4.5	3
7	Current treatment and future directions in the management of anal cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 183-195.	329.8	12
8	Mathematical Modeling to Simulate the Effect of Adding Radiation Therapy to Immunotherapy and Application to Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1055-1062.	0.8	19
9	Measuring the Effect of Local Control From Radiotherapy in Patients With Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2022, , .	7.1	3
10	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS233-TPS233.	1.6	1
11	Spatially defined enrichment of a neuronal-like malignant phenotype in pancreatic cancer after neoadjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2022, 40, 610-610.	1.6	0
12	Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 259-269.	10.7	58
13	A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 564-564.	1.6	0
14	Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. <i>Lancet Oncology</i> , The, 2022, 23, e62-e74.	10.7	36
15	Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1926.	4.1	1
16	Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100169.	2.1	0
17	Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. <i>Clinical Cancer Research</i> , 2022, 28, 3296-3307.	7.0	27
18	Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. <i>Cancer Discovery</i> , 2022, 12, 1462-1481.	9.4	30

#	ARTICLE	IF	CITATIONS
19	Clinical trial perceptions among patients with gastrointestinal (GI) cancer in an academic cancer center.. Journal of Clinical Oncology, 2022, 40, e18579-e18579.	1.6	0
20	Abstract SY12-04: Multicellular spatial community featuring a novel neuronal-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy. Cancer Research, 2022, 82, SY12-04-SY12-04.	0.9	0
21	Colorectal cancer metastatic divnivir immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)â€™NRG-GI004/SWOG-S1610.. Journal of Clinical Oncology, 2022, 40, TPS3647-TPS3647.	1.6	2
22	Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.. Journal of Clinical Oncology, 2022, 40, TPS3643-TPS3643.	1.6	1
23	Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. JCO Oncology Practice, 2022, 18, e1587-e1593.	2.9	6
24	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Journal of the National Cancer Institute, 2021, 113, 182-191.	6.3	49
25	Improving staging of rectal cancer in the pelvis: the role of PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1235-1245.	6.4	40
26	Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. International Journal of Radiation Oncology Biology Physics, 2021, 109, 201-211.	0.8	4
27	Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Journal of Gastrointestinal Surgery, 2021, 25, 2859-2870.	1.7	8
28	Severe lymphopenia predicts poorer survival in patients with rectal cancer undergoing neoadjuvant chemoradiation.. Journal of Clinical Oncology, 2021, 39, 138-138.	1.6	0
29	Prognostic impact of chemoradiation-related lymphopenia in patients with locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, 439-439.	1.6	0
30	Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Molecular Imaging and Biology, 2021, 23, 456-466.	2.6	22
31	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precision Oncology, 2021, 5, 123-132.	3.0	30
32	The use of elevated circulating hepatocyte growth factor (HGF) level as a potential prognostic biomarker in locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, 429-429.	1.6	2
33	Quantitative tumor heterogeneity MRI profiling improves machine learningâ€™based prognostication in patients with metastatic colon cancer. European Radiology, 2021, 31, 5759-5767.	4.5	15
34	Safety and Feasibility of Same-session Endoscopic Ultrasound-guided Biopsy and Fiducial Placement in Pancreatic Cancer. Techniques and Innovations in Gastrointestinal Endoscopy, 2021, 23, 139-144.	0.9	1
35	Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. Annals of Surgical Oncology, 2021, 28, 4592-4601.	1.5	9
36	Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. Clinical Cancer Research, 2021, 27, 2807-2815.	7.0	12

#	ARTICLE	IF	CITATIONS
37	Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 57-69.	3.7	21
38	Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 315-325.	2.1	5
39	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5586-5594.	7.0	178
40	Liver Metastasis—Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients. <i>Pancreas</i> , 2021, 50, 736-743.	1.1	7
41	Local and systemic recurrence following total neoadjuvant therapy (TNT) and resection for borderline resectable and locally advanced pancreatic adenocarcinoma: Long-term follow up from two phase II studies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4133-4133.	1.6	0
42	Toward a Science of Personalized Informed Consent in Cancer Clinical Trials. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00975.	2.9	2
43	Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15611-e15611.	1.6	1
44	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 6343-6353.	7.0	8
45	Clinical impact of PET/MRI in oligometastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021, 125, 975-982.	6.4	17
46	Screening and Validation of Molecular Targeted Radiosensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e63-e74.	0.8	10
47	To Radiate, Not to Radiate, or to Dose-Escalate?. <i>Annals of Surgery</i> , 2021, 274, 902-903.	4.2	1
48	Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1225.	7.1	82
49	ASO Visual Abstract: Neoadjuvant versus Postoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 690-691.	1.5	0
50	Supportive oncology care at home intervention for patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 155-155.	1.6	2
51	Increased T-cell receptor repertoire diversity to predict better overall survival in gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 474-474.	1.6	0
52	Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2856-2865.	1.5	3
53	NRG Oncology NRG-GI007 trial-in-progress: Phase I study of OBP-301 (Telomelysin) and definitive chemoradiation (CRT) for patients with locally advanced esophageal and gastroesophageal adenocarcinoma who are not candidates for surgery.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS262-TPS262.	1.6	1
54	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3773-3777.	1.6	17

#	ARTICLE	IF	CITATIONS
55	Abstract PO-097: Addition of losartan to FOLFIRINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. , 2021, , .		0
56	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135.	13.2	112
57	Proton beam therapy for tumors of the upper abdomen. <i>British Journal of Radiology</i> , 2020, 93, 20190226.	2.2	5
58	Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 204-210.	1.3	20
59	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1871-1884.	6.4	32
60	Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. <i>Practical Radiation Oncology</i> , 2020, 10, e183-e187.	2.1	2
61	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 1400-1406.	1.5	22
62	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 1122-1129.	1.5	29
63	Revisiting <i>MET</i> : Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, <i>MET</i> -Amplified Esophagogastric Cancers. <i>Oncologist</i> , 2020, 25, e1691-e1700.	3.7	1
64	Silver Linings: An Opportunity to Improve Clinical Paradigms After the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2020, 16, 532-534.	2.9	0
65	A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 151, 73-81.	0.6	26
66	Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 897-903.	1.1	10
67	Association of Time Between Radiation and Salvage APR and Margin Status in Patients With Anal Cancer Treated With Concurrent Chemoradiation. <i>American Surgeon</i> , 2020, 86, 703-714.	0.8	4
68	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	1.5	4
69	Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 986-995.	0.8	23
70	Chemoradiation-Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , 2020, 25, 1015-1022.	3.7	11
71	Patterns of Care for Stage II-III Rectosigmoid Cancers in the United States, 2004-2015. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 311-318.	1.3	3
72	Abdominal and Pelvic Reirradiation for Recurrent Gastrointestinal Cancers. <i>Seminars in Radiation Oncology</i> , 2020, 30, 232-237.	2.2	1

#	ARTICLE	IF	CITATIONS
73	Challenges in Reirradiation of Intrahepatic Tumors. <i>Seminars in Radiation Oncology</i> , 2020, 30, 242-252.	2.2	5
74	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1569-1579.	1.6	158
75	Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. <i>Pancreatology</i> , 2020, 20, 722-728.	1.1	22
76	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal/Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218
77	A Multidisciplinary Team Approach for Triage of Elective Cancer Surgery at the Massachusetts General Hospital During the Novel Coronavirus COVID-19 Outbreak. <i>Annals of Surgery</i> , 2020, 272, e20-e21.	4.2	33
78	Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target. <i>Nature Communications</i> , 2020, 11, 3303.	12.8	55
79	Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. <i>Histopathology</i> , 2020, 77, 35-45.	2.9	9
80	Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 230, 912-924.	0.5	42
81	Socioeconomic determinants of the surgical treatment of colorectal liver metastases. <i>American Journal of Surgery</i> , 2020, 220, 952-957.	1.8	9
82	Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. <i>Pancreatology</i> , 2020, 20, 691-697.	1.1	9
83	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	7.0	67
84	Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010. <i>Journal of Clinical Oncology</i> , 2020, 38, 4500-4500.	1.6	33
85	A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy. <i>Journal of Clinical Oncology</i> , 2020, 38, 547-547.	1.6	10
86	Noninvasive comprehensive genomic profiling from plasma ctDNA in pancreatic cancer patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 753-753.	1.6	1
87	The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 833-833.	1.6	0
88	Chemoradiation-related lymphopenia and its association with survival in patients with anal cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3-3.	1.6	0
89	Single-nucleus RNA-seq of frozen archival primary pancreatic ductal adenocarcinoma uncovers multi-compartment intratumoral heterogeneity associated with neoadjuvant treatment. <i>Journal of Clinical Oncology</i> , 2020, 38, 4633-4633.	1.6	0
90	Identifying pan-cancer transcriptomic determinants of perineural and lymphovascular invasion using machine learning. <i>Journal of Clinical Oncology</i> , 2020, 38, 3621-3621.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Phase II study of lamivudine in p53 mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2020, 38, 149-149.	1.6	2
92	Clinical and genomic factors associated with outcome following ablative radiotherapy for oligometastatic and oligoprogressive liver tumors.. Journal of Clinical Oncology, 2020, 38, 515-515.	1.6	3
93	Preliminary analysis of total neoadjuvant therapy for patients with locally advanced gastric (G) and gastroesophageal (GE) adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, 393-393.	1.6	1
94	Clinical impact of PET/MR in treated colorectal cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2260-2269.	6.4	28
95	Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. International Journal of Radiation Oncology Biology Physics, 2019, 105, 90-95.	0.8	20
96	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clinical Cancer Research, 2019, 25, 5561-5571.	7.0	64
97	Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?. The Lancet Gastroenterology and Hepatology, 2019, 4, 575-577.	8.1	2
98	Concurrent therapy with immune checkpoint inhibitors and TNF $\alpha$ blockade in patients with gastrointestinal immune-related adverse events. , 2019, 7, 226.		89
99	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine, 2019, 25, 1415-1421.	30.7	359
100	In Reply to Tsang et al. International Journal of Radiation Oncology Biology Physics, 2019, 105, 231.	0.8	0
101	Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Modern Pathology, 2019, 32, 844-854.	5.5	4
102	Elective nodal irradiation with simultaneous integrated boost stereotactic body radiotherapy for pancreatic cancer: Analyses of planning feasibility and geometrically driven <sc>DVH</sc> prediction model. Journal of Applied Clinical Medical Physics, 2019, 20, 71-83.	1.9	6
103	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. JAMA Oncology, 2019, 5, 1020.	7.1	353
104	The American Brachytherapy Society consensus statement on intraoperative radiation therapy. Brachytherapy, 2019, 18, 242-257.	0.5	53
105	Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy. Clinical and Translational Radiation Oncology, 2019, 18, 113-119.	1.7	1
106	Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2019, 37, 2082-2088.	1.6	135
107	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer, 2019, 125, 2732-2746.	4.1	19
108	Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. American Journal of Surgery, 2019, 218, 959-966.	1.8	14



#	ARTICLE	IF	CITATIONS
109	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 64-72.	0.8	99
110	Cost-effectiveness of Short-Course Radiation Therapy vs Long-Course Chemoradiation for Locally Advanced Rectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e192249.	5.9	37
111	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. <i>Oncologist</i> , 2019, 24, e275-e283.	3.7	18
112	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. <i>Oncologist</i> , 2019, 24, 193-201.	3.7	16
113	Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 564-572.	1.3	0
114	Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26835-26845.	7.1	69
115	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. <i>Oncologist</i> , 2019, 24, 945-954.	3.7	13
116	A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 605-613.	2.5	14
117	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. <i>Annals of Surgery</i> , 2019, 269, 733-740.	4.2	235
118	A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 391-391.	1.6	8
119	Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 412-412.	1.6	1
120	Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC). <i>Journal of Clinical Oncology</i> , 2019, 37, 562-562.	1.6	2
121	A phase II clinical trial platform for sensitization testing using total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS721-TPS721.	1.6	0
122	Patterns of care and outcomes of definitive external beam radiotherapy and radioembolization for localized hepatocellular carcinoma: A propensity score-adjusted analysis. <i>Journal of Clinical Oncology</i> , 2019, 37, 329-329.	1.6	0
123	External beam radiotherapy for hepatocellular carcinoma with right atrium tumor thrombus. <i>Journal of Clinical Oncology</i> , 2019, 37, 328-328.	1.6	1
124	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF</i> <sup>V600E</sup> Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 417-427.	9.4	61
125	Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. <i>Practical Radiation Oncology</i> , 2018, 8, 206-212.	2.1	3
126	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2018, 4, 963.	7.1	426



#	ARTICLE	IF	CITATIONS
127	Will There Be a Clinically Significant Role for Protons in Patients With Gastrointestinal Malignancies?. <i>Seminars in Radiation Oncology</i> , 2018, 28, 125-130.	2.2	1
128	Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer—The New Standard of Care?. <i>JAMA Oncology</i> , 2018, 4, e180070.	7.1	22
129	Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 607-612.	1.3	32
130	Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 656-661.	1.3	13
131	Sarcopenia Is Associated with Quality of Life and Depression in Patients with Advanced Cancer. <i>Oncologist</i> , 2018, 23, 97-104.	3.7	143
132	Pilot study on the impact of F18-labeled thymidine PET/CT on gross tumor volume identification and definition for pancreatic cancer. <i>Practical Radiation Oncology</i> , 2018, 8, 179-184.	2.1	3
133	Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 280-291.	3.8	4
134	Novel use of proton beam therapy for neoadjuvant treatment of radiation-associated squamous cell carcinoma of the esophagus. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 155-160.	1.4	7
135	Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma?. <i>Annals of Surgical Oncology</i> , 2018, 25, 3936-3942.	1.5	10
136	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4027-4034.	1.5	21
137	Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy. <i>Seminars in Radiation Oncology</i> , 2018, 28, 332-341.	2.2	16
138	Radiotherapy for Biliary Tract Cancers. <i>Seminars in Radiation Oncology</i> , 2018, 28, 342-350.	2.2	14
139	Cholangiocarcinoma and Gallbladder Cases: An Expert Panel Case-Based Discussion. <i>Seminars in Radiation Oncology</i> , 2018, 28, 351-361.	2.2	5
140	Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. <i>Npj Precision Oncology</i> , 2018, 2, 22.	5.4	20
141	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. <i>Cancer Medicine</i> , 2018, 7, 2934-2942.	2.8	21
142	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. <i>Practical Radiation Oncology</i> , 2018, 8, 414-421.	2.1	17
143	Potentially curative combination of TGF- $\beta$ 1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4116-4116.	1.6	9
144	Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15674-e15674.	1.6	7

#	ARTICLE	IF	CITATIONS
145	Lymphopenia and outcomes of patients with unresectable hepatocellular carcinoma treated with radiotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 278-278.	1.6	1
146	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. <i>Cancer Research</i> , 2017, 77, 2018-2028.	0.9	80
147	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	82
148	Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. <i>British Journal of Radiology</i> , 2017, 90, 20170134.	2.2	10
149	Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 5959-5969.	7.0	75
150	Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose?. <i>Practical Radiation Oncology</i> , 2017, 7, e323-e329.	2.1	7
151	Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis. <i>Lancet Oncology</i> , The, 2017, 18, e192.	10.7	7
152	Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. <i>Advances in Radiation Oncology</i> , 2017, 2, 110-117.	1.2	45
153	Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. <i>Practical Radiation Oncology</i> , 2017, 7, e291-e297.	2.1	11
154	Spatiotemporal fractionation schemes for liver stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 125, 357-364.	0.6	15
155	Role and Future Directions of External Beam Radiotherapy for Primary Liver Cancer. <i>Cancer Control</i> , 2017, 24, 107327481772924.	1.8	14
156	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. <i>Cancer Letters</i> , 2017, 409, 9-19.	7.2	48
157	Assessment of the Utility of Laparoscopy and Peritoneal Cytology in the Staging of Pancreatic Cancer. <i>Pancreas</i> , 2017, 46, e60-e62.	1.1	1
158	(P026) Alkaline Phosphatase at the Start of Liver Directed Radiation Is A Predictor of Long Term Liver Volume Changes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, E22.	0.8	0
159	Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. <i>Pancreas</i> , 2017, 46, 183-189.	1.1	13
160	Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. <i>Liver Cancer</i> , 2017, 6, 360-374.	7.7	66
161	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2324-2328.	1.6	160
162	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4113-4113.	1.6	1

#	ARTICLE	IF	CITATIONS
163	Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).. Journal of Clinical Oncology, 2017, 35, 4118-4118.	1.6	5
164	Quantitative MR imaging biomarkers of tumor heterogeneity predict prognosis in metastatic colorectal lesions.. Journal of Clinical Oncology, 2017, 35, e15121-e15121.	1.6	1
165	Extramural venous invasion on pretreatment MRI and surgical pathology: Is there a role in predicting prognosis in rectal cancer?. Journal of Clinical Oncology, 2017, 35, e15165-e15165.	1.6	1
166	NRG-GI002: A phase II clinical trial platform for total neoadjuvant therapy (TNT) in rectal cancer.. Journal of Clinical Oncology, 2017, 35, TPS3629-TPS3629.	1.6	5
167	Primary Liver Cancer: Radiation Therapy Planning. , 2017, , 119-130.		0
168	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis.. Journal of Clinical Oncology, 2017, 35, 4117-4117.	1.6	0
169	Guidelines for management of urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.. Journal of Clinical Oncology, 2017, 35, e15641-e15641.	1.6	0
170	Understanding the Paradigm Shift in Pancreatic Cancer. Journal of Oncology Practice, 2016, 12, 926-927.	2.5	1
171	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. Journal of Gastrointestinal Oncology, 2016, 7, 819-827.	1.4	17
172	Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer. Diseases of the Colon and Rectum, 2016, 59, 187-193.	1.3	25
173	Case 39-2016. New England Journal of Medicine, 2016, 375, 2481-2488.	27.0	1
174	A protein and mRNA expression-based classification of gastric cancer. Modern Pathology, 2016, 29, 772-784.	5.5	142
175	Irradiation of FDG-PETâ€œDefined Active Boneâ€œMarrow Subregions and Acute Hematologicâ€œToxicity in Anal Cancer Patients Undergoing Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2016, 94, 747-754.	0.8	25
176	Advancing Techniques of Radiation Therapy for Rectal Cancer. Seminars in Radiation Oncology, 2016, 26, 220-225.	2.2	5
177	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology, The, 2016, 17, 801-810.	10.7	719
178	Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC): Observations from patients enrolled on a prospective phase 2 trial. Practical Radiation Oncology, 2016, 6, e9-e16.	2.1	9
179	Liver-Directed Radiotherapy for Hepatocellular Carcinoma. Liver Cancer, 2016, 5, 198-209.	7.7	27
180	Whatâ€™s the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 3780-3785.	1.5	23

#	ARTICLE	IF	CITATIONS
181	Case 35-2016. New England Journal of Medicine, 2016, 375, 1983-1991.	27.0	2
182	Combined Modality Therapy for Rectal Cancer. Cancer Journal (Sudbury, Mass ), 2016, 22, 211-217.	2.0	6
183	The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality. Journal of Surgical Oncology, 2016, 113, 560-564.	1.7	8
184	The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 243-247.	1.3	5
185	Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 78-85.	0.8	33
186	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2541-2556.	1.6	302
187	Advances in the Management of Gastric and Gastroesophageal Cancers. Current Oncology Reports, 2016, 18, 13.	4.0	7
188	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 2016, 34, 460-468.	1.6	363
189	Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. Journal of Gastrointestinal Surgery, 2016, 20, 172-179.	1.7	16
190	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery, 2016, 6, 147-153.	9.4	338
191	Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. Practical Radiation Oncology, 2016, 6, 166-175.	2.1	26
192	XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer. Clinical Cancer Research, 2016, 22, 1663-1673.	7.0	43
193	Predictors of Lymph Node Metastasis in Western Early Gastric Cancer. Journal of Gastrointestinal Surgery, 2016, 20, 531-538.	1.7	37
194	Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. Journal of Clinical Oncology, 2016, 34, 219-226.	1.6	242
195	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2016, 22, 470-478.	7.0	168
196	Clinical correlation with codon-specific mutations in metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3596-3596.	1.6	1
197	Circulating biomarkers in a phase II study of hypofractionated proton beam therapy (H-PBT) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2016, 34, 4083-4083.	1.6	1
198	A phase II clinical trial platform utilizing total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002.. Journal of Clinical Oncology, 2016, 34, TPS3638-TPS3638.	1.6	3

#	ARTICLE	IF	CITATIONS
199	Gemcitabine (G) + nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.. Journal of Clinical Oncology, 2016, 34, 348-348.	1.6	3
200	Intraoperative radiotherapy (IORT) in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for locally advanced and borderline resectable adenocarcinoma of the pancreas (PDAC).. Journal of Clinical Oncology, 2016, 34, 393-393.	1.6	1
201	A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, 376-376.	1.6	2
202	Effect of ablative radiotherapy on survival in patients with inoperable intrahepatic cholangiocarcinoma: A dose response analysis.. Journal of Clinical Oncology, 2016, 34, 294-294.	1.6	1
203	ACR Appropriateness Criteria® Local Excision in Early Stage Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 520-525.	1.3	1
204	Radiotherapy for liver tumors. Hepatic Oncology, 2015, 2, 133-146.	4.2	7
205	Towards an Integrated Understanding of Epidermal Growth Factor Receptor Biology for Radiation Therapy: Integrins Enter. Journal of the National Cancer Institute, 2015, 107, dju440-dju440.	6.3	4
206	Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 911-920.	0.8	112
207	Familial Gastric Cancers. Oncologist, 2015, 20, 1365-1377.	3.7	46
208	CT-Guided Implantation of Intrahepatic Fiducial Markers for Proton Beam Therapy of Liver Lesions: Assessment of Success Rate and Complications. American Journal of Roentgenology, 2015, 204, W207-W213.	2.2	15
209	Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. Practical Radiation Oncology, 2015, 5, e113-e118.	2.1	38
210	Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers. Molecular Cancer Research, 2015, 13, 713-720.	3.4	34
211	Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer. Annals of Surgery, 2015, 261, 12-17.	4.2	717
212	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discovery, 2015, 5, 1271-1281.	9.4	162
213	NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 29-36.	0.8	83
214	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist, 2015, 20, 1019-1027.	3.7	112
215	Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given?. Journal of Clinical Oncology, 2015, 33, 1878-1880.	1.6	33
216	Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2015, 33, 4020-4020.	1.6	2

#	ARTICLE	IF	CITATIONS
217	The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality.. Journal of Clinical Oncology, 2015, 33, 156-156.	1.6	0
218	Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers.. Journal of Clinical Oncology, 2015, 33, 4043-4043.	1.6	0
219	Charged particle therapy for hepatocellular carcinoma: a commentary on a recently published meta-analysis. Annals of Translational Medicine, 2015, 3, 365.	1.7	0
220	Early-Stage Rectal Cancer. Diseases of the Colon and Rectum, 2014, 57, 449-459.	1.3	37
221	Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiotherapy and Oncology, 2014, 110, 160-164.	0.6	25
222	Intraductal Papillary Mucinous Neoplasm: Clinical Surveillance and Management Decisions. Seminars in Radiation Oncology, 2014, 24, 77-84.	2.2	11
223	Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2014, 20, 1884-1890.	7.0	110
224	A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Practical Radiation Oncology, 2014, 4, 316-322.	2.1	42
225	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Practical Radiation Oncology, 2014, 4, e117-e123.	2.1	4
226	Interobserver Variability in Target Definition for Hepatocellular Carcinoma With and Without Portal Vein Thrombus: Radiation Therapy Oncology Group Consensus Guidelines. International Journal of Radiation Oncology Biology Physics, 2014, 89, 804-813.	0.8	33
227	Radiation Therapy for Liver Tumors: Ready for Inclusion in Guidelines?. Oncologist, 2014, 19, 868-879.	3.7	64
228	Pancreatic Adenocarcinoma. New England Journal of Medicine, 2014, 371, 1039-1049.	27.0	1,821
229	Genetic Mechanisms in Interval Colon Cancers. Digestive Diseases and Sciences, 2014, 59, 2255-2263.	2.3	19
230	Adjuvant Therapy for Gastric Cancers: More Answers or More Questions?. Annals of Surgical Oncology, 2014, 21, 3367-3368.	1.5	1
231	Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer. Journal of Gastrointestinal Cancer, 2014, 45, 34-39.	1.3	36
232	Upper abdominal normal organ contouring guidelines and atlas: A Radiation Therapy Oncology Group consensus. Practical Radiation Oncology, 2014, 4, 82-89.	2.1	103
233	An Emerging Role for Radiation Therapy in the Treatment of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Surgical Oncology Clinics of North America, 2014, 23, 353-368.	1.5	16
234	Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy. Practical Radiation Oncology, 2014, 4, 167-173.	2.1	22



#	ARTICLE	IF	CITATIONS
235	Mutational analysis and clinical correlation of metastatic colorectal cancer. <i>Cancer</i> , 2014, 120, 1482-1490.	4.1	63
236	Validation of the NSABP neoadjuvant rectal score (NAR) in a prospective phase II study evaluating an experimental regimen and a standard chemoradiation cohort with molecular genotyping. <i>Journal of Clinical Oncology</i> , 2014, 32, 3599-3599.	1.6	2
237	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 4128-4128.	1.6	3
238	Variability in immune infiltrates and HLA expression in cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 230-230.	1.6	2
239	A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4157-TPS4157.	1.6	0
240	Surgical resection and intraoperative radiation therapy for locally recurrent rectal carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3643-3643.	1.6	5
241	ACR Appropriateness Criteria®-Anal Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 4-14.	0.7	7
242	Stereotactic body radiation therapy (SBRT) for pancreatic and non-hepatobiliary gastrointestinal (GI) malignancies. <i>Journal of Radiation Oncology</i> , 2013, 2, 381-390.	0.7	0
243	Gastric lymph node contouring atlas: A tool to aid in clinical target volume definition in 3-dimensional treatment planning for gastric cancer. <i>Practical Radiation Oncology</i> , 2013, 3, e11-e19.	2.1	23
244	Noncurative Gastrectomy for Gastric Adenocarcinoma Should only be Performed in Highly Selected Patients. <i>Annals of Surgical Oncology</i> , 2013, 20, 3512-3518.	1.5	28
245	Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. <i>Cancer</i> , 2013, 119, 4196-4204.	4.1	58
246	Dosimetric predictors of nausea and vomiting: an exploratory analysis of a prospective phase I/II trial with neoadjuvant accelerated short-course radiotherapy and capecitabine for resectable pancreatic cancer. <i>Journal of Radiation Oncology</i> , 2013, 2, 427-434.	0.7	5
247	Optimizing Adjuvant Treatment Decisions for Stage T2 Rectal Cancer Based on Mesorectal Node Size. <i>Academic Radiology</i> , 2013, 20, 79-89.	2.5	1
248	Feasibility study of in vivo MRI based dosimetric verification of proton end-of-range for liver cancer patients. <i>Radiotherapy and Oncology</i> , 2013, 106, 378-382.	0.6	31
249	Targeted Therapies with Chemoradiation in Esophageal Cancer: Development and Future Directions. <i>Seminars in Radiation Oncology</i> , 2013, 23, 31-37.	2.2	12
250	Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer. <i>Oncologist</i> , 2013, 18, 281-287.	3.7	33
251	Radiotherapy for Hepatocellular Carcinoma With Tumor Vascular Thrombus: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1619-1620.	1.6	9
252	FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience. <i>Oncologist</i> , 2013, 18, 543-548.	3.7	265



#	ARTICLE	IF	CITATIONS
253	Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2013, 257, 731-736.	4.2	344
254	Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers. <i>PLoS ONE</i> , 2013, 8, e82982.	2.5	27
255	Mutational analysis of locally advanced rectal cancer and response to neoadjuvant chemoradiation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 449-449.	1.6	0
256	Prognostic markers of time to local recurrence and overall survival in early-stage rectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 473-473.	1.6	0
257	The impact of positive margins on outcome among patients with gastric cancer treated with radiation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 81-81.	1.6	0
258	Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4047-4047.	1.6	0
259	DNA mutation frequencies in metastatic small bowel adenocarcinoma (mSBA) in comparison to gastric (mGC), colon (mCC), and rectal cancer (mRC): Continuum or cutpoint?. <i>Journal of Clinical Oncology</i> , 2013, 31, e14636-e14636.	1.6	0
260	Cancers of the Colon and Rectum: Identical or Fraternal Twins?. <i>Cancer Discovery</i> , 2012, 2, 117-121.	9.4	52
261	Multidisciplinary Management of Early-Stage Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1577-1585.	4.9	4
262	Dose-Volume Effects on Patient-Reported Acute Gastrointestinal Symptoms During Chemoradiation Therapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e513-e517.	0.8	21
263	Mitomycin in Anal Cancer: Still the Standard of Care. <i>Journal of Clinical Oncology</i> , 2012, 30, 4297-4301.	1.6	9
264	Heterogeneity in head and neck IMRT target design and clinical practice. <i>Radiotherapy and Oncology</i> , 2012, 103, 92-98.	0.6	130
265	Impact of Age and Comorbidities on the Treatment of Gastrointestinal Malignancies. <i>Seminars in Radiation Oncology</i> , 2012, 22, 311-320.	2.2	11
266	Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma. <i>Practical Radiation Oncology</i> , 2012, 2, e89-e94.	2.1	5
267	Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. <i>Cancer</i> , 2012, 118, 3026-3035.	4.1	59
268	Radiation oncology whiteboard: Data and workflow manager for enhanced communication and task management.. <i>Journal of Clinical Oncology</i> , 2012, 30, 304-304.	1.6	6
269	FOLFIRINOX in locally advanced or metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 313-313.	1.6	4
270	Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 301-301.	1.6	0

#	ARTICLE	IF	CITATIONS
271	FOLFIRINOX in locally advanced and metastatic pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, e14615-e14615.	1.6	2
272	Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.. Journal of Clinical Oncology, 2012, 30, 4021-4021.	1.6	1
273	ACR Appropriateness Criteria®-Recurrent Rectal Cancer. Gastrointestinal Cancer Research: GCR, 2012, 5, 3-12.	0.7	3
274	Case 13-2011. New England Journal of Medicine, 2011, 364, 1658-1668.	27.0	0
275	Radiation recall associated with insulin growth factor 1R antibody. Practical Radiation Oncology, 2011, 1, 208-211.	2.1	2
276	T3N0 Rectal Cancer: Radiation for All?. Seminars in Radiation Oncology, 2011, 21, 212-219.	2.2	21
277	Charged-Particle Therapy for Hepatocellular Carcinoma. Seminars in Radiation Oncology, 2011, 21, 278-286.	2.2	55
278	Phase I Study of Preoperative Short-Course Chemoradiation With Proton Beam Therapy and Capecitabine for Resectable Pancreatic Ductal Adenocarcinoma of the Head. International Journal of Radiation Oncology Biology Physics, 2011, 79, 151-157.	0.8	67
279	Short-Course Versus Standard Chemoradiation in T3 Rectal Cancer. Oncologist, 2011, 16, 717-721.	3.7	2
280	Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. Gastrointestinal Cancer Research: GCR, 2011, 4, 116-21.	0.7	9
281	Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer. Cancer, 2010, 116, 1879-1886.	4.1	29
282	Current Management of Gallbladder Carcinoma. Oncologist, 2010, 15, 168-181.	3.7	279
283	The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal cancer surgery. American Journal of Surgery, 2010, 200, 440-445.	1.8	26
284	Case 19-2009. New England Journal of Medicine, 2009, 360, 2656-2664.	27.0	4
285	Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: A Radiation Therapy Oncology Group Consensus Panel Contouring Atlas. International Journal of Radiation Oncology Biology Physics, 2009, 74, 824-830.	0.8	425
286	External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis. Cancer, 2008, 112, 943-949.	4.1	11
287	Multicriteria Optimization in Intensity-Modulated Radiation Therapy Treatment Planning for Locally Advanced Cancer of the Pancreatic Head. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1208-1214.	0.8	66
288	Impact of Manual and Automated Interpretation of Fused PET/CT Data on Esophageal Target Definitions in Radiation Planning. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1612-1618.	0.8	30

#	ARTICLE	IF	CITATIONS
289	Megavoltage Computed Tomography. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 617-623.	1.3	31
290	Considerations in Treatment Planning for Esophageal Cancer. Seminars in Radiation Oncology, 2007, 17, 53-61.	2.2	26
291	Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard. Gastrointestinal Cancer Research: GCR, 2007, 1, 49-56.	0.7	5
292	Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy. Acta Oncol <sup>3</sup> gica, 2006, 45, 717-727.	1.8	27
293	Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: A phase III combined modality study. Pediatric Blood and Cancer, 2005, 45, 676-682.	1.5	18
294	Cancer in the Nervous System, Second Edition. Neuro-Oncology, 2003, 5, 275-276.	1.2	0
295	Treatment of Recurrent Malignant Gliomas With Stereotactic Intensity Modulated Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 606-611.	1.3	60